Disorder Related to Renal Transplantation Clinical Trial
Official title:
Prospective Donor-specific Cellular Alloresponse Assessment for Immunosuppression Minimization in de Novo Renal Transplantation
Verified date | January 2021 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of the study is to demonstrate the utility and safety of the IFN-γ (Interferon Gamma) ELISPOT (Enzyme-linked immunosorbent spot) marker for the stratification of kidney transplant recipients into low and high IS (Immunosuppression) regimens. The enrichment study will test non-inferiority of low IS regimen compared to high IS regimen, assuming 10% of BPAR at 6-months in the control group, and allowing a non-inferiority limit of maximum 10%.
Status | Completed |
Enrollment | 184 |
Est. completion date | October 31, 2020 |
Est. primary completion date | October 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Men and women, age =18 years. 2. Subject must be a recipient of a first renal transplant from a deceased or living donor. 3. Subject must have a current documented PRA (Panel of reactive antibodies) <20% and no detectable anti-class I and II HLA (human leukocyte Antigens) antibodies by solid phase assay (Luminex®). 4. Subject is willing to provide signed written informed consent. 5. Women of Childbearing Potential (WOCBP) must be using a highly effective method of contraception (Pearl-Index < 1) to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea = 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL]. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG (Human chorionic gonadotropin)) within 72 hours prior to the start of clinical trial. Exclusion Criteria: 1. Subjects undergoing renal transplant with a current documented PRA >20% and/or detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®). 2. CDC (complement dependent cytotoxicity) positive cross match. 3. Subjects receiving an allograft from a donor older than 65 years with elevated creatinine levels and/or treated diabetes. 4. Cold ischemia time (CIT) higher than 24h. 5. Subjects with a prior solid organ transplant (SOT), including renal re-transplantation, or receiving a concurrent SOT. 6. Patients previously treated with daclizumab or basiliximab. 7. Subjects with underlying renal disease of: - Primary focal segmental glomerulosclerosis. - Type I or II membranoproliferative glomerulonephritis - Atypical Haemolytic uremic syndrome (HUS) / thrombotic thrombocytopenic purpura syndrome. 8. Subject with Hepatitis B chronic infection and/or active infection by Hepatitis C virus (positive PCR (polymerase chain reaction result) at the moment of transplant. 9. Subjects with known human immunodeficiency virus (HIV) infection. 10. Patients with active systemic infection that requires the continued use of antibiotics. 11. Patients with neoplasia except localized skin cancer receiving appropriate treatment. 12. Patients with severe anemia (hemoglobin < 6g/dl), leucopenia (WBC (White blood cells) <2500/mm3), thrombocytopenia (platelets <80.000/mm3). 13. Hemodynamically instable patients even if their hemoglobin level counts > 6 g/dl. 14. Patients with intestinal pathology or severe diarrhoea that can hinder absorption according to medical criteria. 15. Subjects with a known hypersensibility to any of the drugs used in this protocol. 16. Subjects who have used any investigational drug within 30 days prior to enrolment in this clinical trial. 17. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period, women who are pregnant or breastfeeding or women with a positive pregnancy test on enrolment. 18. Subjects who are legally detained in an official institution |
Country | Name | City | State |
---|---|---|---|
Czechia | Institut klinické a experimentální mediciny | Prague | Prague 4 |
France | Centre Hospitalier Universitaire de Nantes | Nantes | |
Germany | Department Nephrology and BCRT, Charité Universitätsmedizin Berlin | Berlin | |
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Universitätsklinikum Regensburg | Regensburg | |
Netherlands | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Amsterdam | |
Spain | Hospital Universitari de Bellvitge | Hospitalet de Llobregat | Barcelona |
United Kingdom | Guy's Hospital, Great Maze Pond | London |
Lead Sponsor | Collaborator |
---|---|
Prof. Dr. Petra Reinke |
Czechia, France, Germany, Netherlands, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | assessment of anti-donor T-cell alloresponses using the IFN-? ELISPOT test | Patients with a positive anti-donor IFN-? ELISPOT assay result (>25 spots/300.000 PBMC (peripheral blood mononuclear cells )) will be ruled out of the study and patients with negative anti-donor IFN-? ELISPOT test (<25 spots/300.000 PBMC) will be randomized in 2 different groups (1:1).
The main objective of the study is to demonstrate the utility and safety of the IFN-? ELISPOT marker for the stratification of kidney transplant recipients into low and high IS regimens. |
6 months | |
Secondary | Differences across Treatment arms in eGFR (estimated glomerular Filtration rate) (ml/min) | after 3, 6 and 12 months | ||
Secondary | Differences across Treatment arms in Biopsy proven acute rejection rate (BPAR rate) | after 6 and 12 months | ||
Secondary | Differences across Treatment arms in subclinical rejection rate using renal allograft biopsy | after 3 and 12 months | ||
Secondary | Differences across Treatment arms in Prevalence of death, and graft loss | after 6 and 12 months | ||
Secondary | Differences across Treatment arms in Prevalence of metabolic and cardiovascular co-morbidity (new onset diabetes mellitus (NODAT, dyslipidaemias, hypertension) | 12 months | ||
Secondary | Differences across Treatment arms in Prevalence of subjects that remain MMF and steroid-free | after 6 and 12 months | ||
Secondary | Differences across Treatment arms in Prevalence of Acute and chronic histologic lesions assessed by the Bannf'11 score in protocol biopsies | after 3 and 12 months | ||
Secondary | Differences across Treatment arms in Prevalence of patients that remain on Therapy | after 12 months | ||
Secondary | Differences across Treatment arms in Distribution of patients in distinct chronic kidney diseases (CKD) stages | after 12 months | ||
Secondary | Differences across Treatment arms in treatment cost (cost/benefit) | after 1,3,6,12 and 24 months | ||
Secondary | Differences across Treatment arms in development of a Panel reactive T (PRT)-cell response platform to evaluate general anti-HLA T-cell Responses using ELISPOT | at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR | ||
Secondary | Differences across Treatment arms in assessment of anti-donor and anti-HLA antibodies by Solid phase assays (Luminex®) and B-cell ELISPOT | at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR | ||
Secondary | Differences across Treatment arms in different viral load (CMV, EBV, BKV) | at months 1, 2, 3, 6 and 12 after transplantation | ||
Secondary | Differences across Treatment arms in study of virus-specific T-cell responses (ELISPOT) | at at pre-transplantation, 3, 6 and 12 after transplantation | ||
Secondary | Differences across Treatment arms in prevalence of transcriptional genes by RT-PCR in PBMC (peripheral blood mononuclear cells ) | at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR | ||
Secondary | Differences across Treatment arms in flow cytometry assessment of peripheral blood mononuclear cells (PBMC) | at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR | ||
Secondary | Differences across Treatment arms in Quantitative analyses of urinary IP-10 (Interferon Gamma induced Protein) | at 4 weeks and at 3, 6 and 12 month after transplantation as well as at time of BPAR | ||
Secondary | Differences across Treatment arms in Assessment of protocol biopsies | at month 3 and 12 after transplantation | ||
Secondary | Differences across Treatment arms in MicroRNA assessment in sera and urine | at pre-transplantation and months 1, 3, 6 and 12 after transplantation | ||
Secondary | Differences across Treatment arms in evaluation of FOXP3 (Forkhead box P3) methylation degree at the TSDR (Treg-specific demethylated Region) | at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of rejection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02581436 -
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
|
N/A | |
Terminated |
NCT01561404 -
Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise
|
Phase 4 | |
Recruiting |
NCT02849899 -
Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period
|
Phase 3 | |
Not yet recruiting |
NCT01289301 -
Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant
|
Phase 4 | |
Completed |
NCT00905957 -
Transversus Abdominis Plane Block For Renal Transplant Recipients
|
N/A | |
Active, not recruiting |
NCT02843867 -
Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation
|
||
Active, not recruiting |
NCT02751099 -
Bone and Cardiovascular Disease After Kidney Transplant
|
||
Completed |
NCT01646099 -
Sun Protection of Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01744067 -
The Effects of Omega-3 Fatty Acids in Renal Transplantation
|
Phase 4 | |
Active, not recruiting |
NCT03935958 -
Curcumin in Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT02513602 -
Osseointegrated Dental Implants in Kidney Transplanted Patients
|
N/A | |
Completed |
NCT01844713 -
Evaluation of Sun Protection Education for Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT01550445 -
Steroid Withdrawal Immunosuppression After Renal Transplantation
|
Phase 4 | |
Completed |
NCT01195194 -
Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.
|
Phase 4 | |
Completed |
NCT00724022 -
Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
|
Phase 4 | |
Terminated |
NCT00167661 -
Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT03968588 -
Standard- Versus Reduced-dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Renal Transplantation
|
Phase 4 | |
Recruiting |
NCT02515643 -
Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients
|
N/A | |
Completed |
NCT00455013 -
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT02843763 -
Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer
|
N/A |